25

35

CLAIMS

- 1. A cartilage membrane having at least one surface part carrying a composition comprising at least one stimulation molecule which is capable of inducing a signal transduction in chondroblast/chondrocytes resulting in the chondro
- signal transduction in chondroblast/chondrocytes resulting in the chondroblast/chondrocytes producing and secreting matrix components which form hyalin cartilage or more specifically hyalin articular cartilage.
 - 2. A cartilage membrane according to claim 1, which is a non-immunogenic, non-toxic, biodegradable membrane.
- 10 3. A cartilage membrane according to claims 1 or 2, wherein the membrane material is porous or substantially porous
 - 4. A cartilage membrane according to claim 3, wherein the membrane is a natural or synthetic collagen type I membrane or part thereof.
- 5. An interface membrane with a first surface part and a second second surface part both carrying a composition comprising at least one stimulation molecule which is capable of inducing a signal transduction in chondroblast/chondrocytes and osteoblasts/osteocytes.
 - 6. An interface membrane according to claim 5, which is a non-immunogenic, non-toxic, biodegradable membrane.
- 20 7. An interface membrane according to claims 5 or 6, wherein the membrane material is porous or substantially porous.
 - 8. An interface membrane according to claim 7, wherein the membrane is a natural or synthetic collagen type I membrane or part thereof.
 - 9. A membrane according to any of the claims 1-8, wherein the stimulation-molecule comprising at least one RGD motif.
 - 10. A membrane according to claim 9, wherein the stimulation molecule is a natural or synthetic protein or peptide or a fusion or a mixture thereof.
 - 11. A membrane according to claim 10, wherein the stimulation molecule is selected from the group consisting of collagen proteins such as collagen types II, VI, IX,
- and XI, proteoglycans such as aggregans, decorin, fibromodulin and biglycan, and non-collageneous proteins such as cryoprecipitate, fibronectin, vitronectin, fibronogen, fibrillin, kistrin, echistatin, von Willebrand factor, tenascin and anchorin CII.
 - 12. A membrane according to claim 11, wherein the stimulation molecule is selected from the group consisting of collagen type II and fibronectin.
 - 13. A membrane according to claim 12, wherein the stimulation molecule is attached to a support.
 - 14. A method for in vivo repair of cartilage defects in joints in mammals, comprising

5

15

20

applying, over a cartilage free cavity (7) of a joint, a cartilage membrane (5) with a first surface part of which facing the cartilage free cavity (7), the first surface part of the cartilage membrane (5) carrying a composition comprising at least one stimulation molecule which is capable of inducing a signal transduction in chondroblast/chondrocytes,

- introducing, in the cartilage free cavity (7) between the cartilage membrane (5), the cartilage (2) and the interface (3), a chondroblast/chondrocyte suspension (8), and;
- joining a portion part of the first surface part of the cartilage membrane (5) to the surrounding articular surface (1) so as to sealingly entrap the chondro-blast/chondrocyte suspension (8) in the cartilage free cavity (7) using a sealing portion (6), thereby allowing the chondroblast/chondrocyte suspension (8) to produce and secrete matrix components characteristic for hyalin.
 - 15. A method according to claim 14, wherein the cartilage membrane is a cartilage membrane according to any of claims 1-4 and the stimulation molecule is a stimulation molecule according to claims 9-13.

16. A method for in vivo repair of bone and cartilage defects in joints in mammals,

- such as in osteoarthritic joints, comprising applying, over a bone free cavity (23) and under a cartilage free cavity (70) of a joint, an interface membrane (21) with a first surface part (22) facing the bone free cavity (23), the interface membrane (21) first surface part (22) carrying a composition comprising at least one stimulation molecule which is capable of inducing a signal transduction in osteoblast/osteocyte, and the second surface part (26) carrying a composition comprising at least one stimulation molecule
- which is capable of inducing a signal transduction in chondroblast/chondrocytes, introducing, in the interstice between the interface membrane first surface part (22) and the bone (40), an osteoblast/osteocyte suspension (24), joining a portion part of the first surface part (22) of the interface membrane (21) to the surrounding interface surface (30) so as to sealingly entrap the
- osteoblast/osteocyte suspension (24) in the bone free cavity (23) using a sealing portion (25), thereby allowing the osteoblast/osteocyte suspension (24) to produce and secrete matrix components characteristic for bone tissue; applying, over the cartilage free cavity (70), a cartilage membrane (50) with a first surface part facing the second surface part (26) of the interface membrane (21), the first surface part of the cartilage membrane (50) carries a composition comprising at least one stimulation molecule which is capable of inducing a

comprising at least one stimulation molecule which is capable of inducing a signal transduction in chondroblast/chondrocytes resulting in the chondroblast/chondrocytes producing and secreting matrix components which form hyalin cartilage,

35

5

introducing, in the cartilage free cavity (70) between the interface membrane (21), the cartilage membrane (50) and the cartilage (20), a chondro-blast/chondrocyte suspension (80),

- joining a portion part of the cartilage membrane (50) to the surrounding articular surface (10) so as to sealingly entrap the chondroblast/chondrocyte suspension (80) in the cartilage free cavity (70) using a sealing portion (60), thereby allowing the chondroblast/chondrocyte suspension (80) to produce and secrete matrix components which form hyalin.
- 17. A method for in vivo repair of bone and cartilage defects in joints in mammals
 using arthroscopy, such as in osteoarthritic joints, comprising
 treating an interface membrane (21) with a first sealing portion component,
 applying, over a bone free cavity (23) and under a cartilage free cavity (70) of a joint, an interface membrane (21) with a first surface part (22) facing the bone
 free cavity (23), the interface membrane (21) first surface part (22) carrying a
 composition comprising at least one stimulation molecule which is capable of inducing a signal transduction in osteoblast/osteocyte, and the second surface part (26), which carries a composition comprising at least one stimulation molecule which is capable of inducing a signal transduction in chondroblast/chondrocytes,
- introducing, in the interstice between the interface membrane first surface part (22) and the bone (40), an osteoblast/osteocyte suspension (24), joining a portion part of the first surface part (22) of the interface membrane (21) to the surrounding interface surface (30) so as to sealingly entrap the osteoblast/osteocyte suspension (24) in the bone free cavity (23) using a second
- sealing portion component, thereby allowing the osteoblast/osteocyte suspension (24) to produce and secrete components characteristic for bone tissue; introducing, in the cartilage free cavity (70) between the interface membrane (21), and the articular surface, a chondroblast/chondrocyte suspension (80), thereby allowing the chondroblast/chondrocyte suspension (80) to produce and secrete components characteristic for hyalin.
 - 18. A method according to claim 16-17, wherein the membranes are membranes according to any of the claims 1-8 and the stimulation molecule is a stimulation molecule according to any of the 9-13.
 - 19. A method according to any of claims 14-18, wherein the chondroblast/chondrocyte suspension is a suspension of autologous chondroblast/chrondrocytes.
 - 20. A method according any of claims 16-19, wherein the osteoblast/osteocyte suspension is a suspension of autologous osteoblast/osteocyte.

- 21. A kit for cartilage repair comprising at least one cartilage membrane according to any of claims 1-4 and at least one stimulation molecule according to claims 9-13.
- 22. A kit according to claim 21 comprising at least one interface membrane according to claims 5-8.
- 23. Use of at least one membrane according to claims 1-13 for the preparation of a kit according to claims 21 or 22 for the treatment of a mammal having a cartilage defects or bone and cartilage defects.
- 24. Method of treatment according to any of the claims 14-20 for the treatment of a
 mammal having cartilage defects or bone and cartilage defects.
 - 25. A method according to claim 24 wherein the method is used for the treatment of chondral leasions or osteochondreal lesions, osteochondritis dissecans (OCD), chondromalacia and osteoathritis.
- 26. A method for preparation of chondroblast/chondrocyte or osteocyte/osteoblast suspensions comprising harvesting mesenchymal and/ or mesenchymal precursor cells from a source such as bone marrow, perichondrium, periosteum, blood, blood vessels or muscle; adding the harvested cells to a cell culture flask comprising at least one growth medium;
- 20 growing the harvested cells until colony forming units with a cell number size in the ranging order of 10-20.000 cells /clone are formed with fibroblastic phenotype (CFU-f); transferring the CFU-f cells into a new cell culture flask comprising at least one selection medium for differentiation of the CFU-f's into chondroblast/chondrocytes, osteocytes/osteoblasts or myoblasts/myotubes;
- cytes, osteocytes/osteoblasts or myoblasts/myotubes and harvesting of the differentiated cells.
 - 27. A method according to claim 26, wherein the suspensions are used for the treatment of cartilage and/or bone and cartilage defects in mammals.
- 28. A method according to claims 26 or 27, wherein the selection medium comprises components more specific for selection than for growth.